InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by DRACHMAN JONATHAN G, Chairman & CEO. Director active across 2 companies, notably Neoleukin Therapeutics, Inc.. Cumulatively, 6 filings have been logged. Total volume traded: €2m. The latest transaction was filed on 10 November 2021 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations6 total
€148,247200,000 shares@ €0.7412100.0% of flow
Common Stock
SEC:0000899243-21-044150·
Ideal exit: 7 Aug 2022 (T+270)
€148,247200,000 shares@ €0.741250.0% of flow
Common Stock
SEC:0000899243-21-044150:0·
Ideal exit: 7 Aug 2022 (T+270)
€519,948100,000 shares@ €5.199562.5% of flow
Common Stock
SEC:0001209191-21-053544·
Ideal exit: 21 May 2022 (T+270)
€519,948100,000 shares@ €5.199531.2% of flow
Common Stock
SEC:0001209191-21-053544:0·
Ideal exit: 21 May 2022 (T+270)
€312,59540,000 shares@ €7.814937.5% of flow
Common Stock
SEC:0001209191-21-038690·
Ideal exit: 28 Feb 2022 (T+270)
€312,59540,000 shares@ €7.814918.8% of flow
Common Stock
SEC:0001209191-21-038690:0·
Ideal exit: 28 Feb 2022 (T+270)
6 of 6 declarations
About DRACHMAN JONATHAN G
Jonathan G. Drachman is President and CEO of Neoleukin Therapeutics, Inc. and Calithera Biosciences, Inc. He leads these companies with a strategic vision, overseeing all operations and ensuring performance objectives are met. His leadership is crucial for the development of these biopharmaceutical firms.
